Key result
Left main revascularization therapy requires integrating complementary evidence from randomized trials and registries to navigate the many known and unknown clinical factors influencing treatment.
Why the study?
How should left main coronary artery disease be treated with revascularization therapy?
How should left main coronary artery disease be treated with revascularization therapy?
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“I think that we can use this to inform patients that, for those who meet the inclusion criteria of NOBLE, there is no sign that we are losing patients after 10 years by doing PCI. But we still have reduction in spontaneous MI and repeat revascularization up to 5 years in CABG, and we still have less strokes that patients are fearing with PCI. We can add this [10-year mortality] information on, and we can deliver these data to the guideline committees.”
“First and foremost, both PCI and CABG are clinically reasonable for the treatment of these patients. We've maintained a class I recommendation for CABG. I think that was an easy decision. As for the IIa recommendation for PCI, there were a couple of reasons. Number one, the SYNTAX score or SYNTAX tertiles didn't seem to be a strong effect modifier in the lower two tertiles. It was really an arbitrary distinction between low and intermediate risk so we felt that the same recommendation should really apply to both.”
“It showed us that the definitions used in these trials probably weren't relevant for a CABG population.”
This review discusses the complementary lessons from trials and registries regarding left main coronary artery revascularization.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
McEntegart et al. (2023) studied this question. Left main revascularization therapy requires integrating complementary evidence from randomized trials and registries to navigate the many known and unknown clinical factors influencing treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: